Effects of metoclopramide-induced hyperprolactinemia on the prolactin and prolactin receptor expression of murine adrenal
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Citação
GYNECOLOGICAL ENDOCRINOLOGY, v.31, n.12, p.925-928, 2015
Resumo
The aim of this study was to evaluate the effects of metoclopramide-induced hyperprolactinemia on the prolactin (PRL) and prolactin receptor's (PRLR) expression in the adrenal. For this purpose, a total of 12 animals with intact ovaries were allocated to two groups: G1 (saline solution) and G2 (metoclopramide). A total of 30 oophorectomized animals was randomized to five subgroups: G3 (saline solution), G4 (metoclopramide), G5 (metoclopramide + 17 beta-estradiol), G6 (metoclopramide + progesterone), and G7 (metoclopramide + 17 beta-estradiol + progesterone). Immunohistochemical analyses were evaluated semi-quantitatively. For PRLR, the area fraction of labeled cells (ALC) varied from 1 (0-10%) to 3 (> 50%). Based on the mean of the immunostaining intensity, G2 and G4 showed strong expression; G6 and G7 presented a mild reaction; and G1, G3, and G5 exhibited a weak reaction. Concerning PRL, the ALC varied from 1 (0-10%) to 3 (> 50%), and groups G6 and G7 showed a strong reaction; G2, G4, and G5 showed a mild reaction; and G1 and G3 exhibited a weak reaction. These findings suggest that metoclopramide-induced hyperprolactinemia increases PRL expression in the adrenal glands of mice. Furthermore, progesterone alone or in association with estrogen also increases PRL expression, but to a lesser extent.
Palavras-chave
Adrenal gland, estrogens, hormone replacement therapy
Referências
- Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656
- Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049
- Glasow A, 1996, J CLIN ENDOCR METAB, V81, P3103, DOI 10.1210/jc.81.8.3103
- OGO A, 1993, ENDOCR J, V40, P17, DOI 10.1507/endocrj.40.17
- Niemczyk S, 2012, ENDOKRYNOL POL, V63, P250
- Panzan MQ, 2006, HUM REPROD, V21, P2514, DOI 10.1093/humrep/del093
- KANEMARU Y, 1989, ENDOCRINOL JAPON, V36, P459
- Iwanaga T, 2011, BIOMED RES-TOKYO, V32, P225
- Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/er.19.3.225
- ADVIS JP, 1983, BIOL REPROD, V29, P181, DOI 10.1095/biolreprod29.1.181
- Wittes J, 2002, EPIDEMIOL REV, V24, P39, DOI 10.1093/epirev/24.1.39
- Binart N, 2010, TRENDS ENDOCRIN MET, V21, P362, DOI 10.1016/j.tem.2010.01.008
- Finken MJJ, 2013, EUR J OBSTET GYN R B, V166, P230, DOI 10.1016/j.ejogrb.2012.10.033
- Bernichtein S, 2010, J ENDOCRINOL, V206, P1, DOI 10.1677/JOE-10-0069
- HIGUCHI K, 1984, J CLIN ENDOCR METAB, V59, P714
- Suzuki T, 2008, INVEST OPHTH VIS SCI, V49, P1797, DOI 10.1167/iovs.07-1458
- Tohei A, 2004, J REPROD DEVELOP, V50, P9, DOI 10.1262/jrd.50.9
- Rossi AGZ, 2010, FERTIL STERIL, V93, P1643, DOI 10.1016/j.fertnstert.2009.02.021
- Silva EJ, 2004, BRAZ J MED BIOL RES, V37, P193, DOI 10.1590/S0100-879X2004000200005
- Amaral VC, 2013, GEN COMP ENDOCR, V189, P105, DOI 10.1016/j.ygcen.2013.04.037
- OGLE TF, 1979, ENDOCRINOLOGY, V104, P40
- do Amaral VC, 2015, GYNECOL ENDOCRINOL, V31, P148, DOI 10.3109/09513590.2014.967204
- Fernandez Lopez GM, 1996, REV CUB ENDOCRINOL, V7, P90
- Kansra S, 2010, PLOS ONE, V5, P100
- Lefrancois-Martinez AM, 2011, J BIOL CHEM, V286, P32976, DOI 10.1074/jbc.M111.218016
- Meuwese CL, 2013, ARCH MED RES, V44, P591, DOI 10.1016/j.arcmed.2013.10.009
- Radl DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018097
- Sherwood L, 2011, FISIOLOGIA HUMANA CE